Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jan 24;17(6):801–809. doi: 10.1093/neuonc/nou363

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

PMC Copyright notice

Fig. 1. — (A) Kaplan–Meier survival curves for patients with a high ratio (above median value) versus low ratio (below or equal to median value) of tumor-infiltrating CD3+ cells that are Tregs as determined by epigenetic qPCR method, P = .182. (B) Kaplan–Meier survival curves for patients based on the proportion of tumor-infiltrating CD3+ T cells as determined by epigenetic qPCR (P = .261). Patients were divided into those with a percentage of CD3+ T cells above the median value and those with a percentage of CD3+ T cells below or equal to the median value. (C) Kaplan–Meier survival curves for the pretreatment (postsurgery) percentage of Tregs in the peripheral blood T-cell population determined by flow cytometry (P = .938, percent of CD3+ cells that are CD4+CD25+FoxP3+). Patients were divided into those with a high percentage of Tregs (above median value) and a low percentage of Tregs (below or equal to median value).